Table 6. . Cost and cost–effectiveness results. Base case. Time horizon: 5 years.

Treatment	Cost per patient	Cost differences†	QALYs per patient	QALY difference	Fractures	Fractures avoided	Cost per QALY gained	Cost per Fracture avoided
RIS-GR ALN	2940.80 € 4935.43 €	-1994.63 €	3.7753 3.7634	0.0119	363 442	-79	Risedronate GR is the dominant treatment‡	Risedronate GR is the dominant treatment‡

^†Probability of savings with weekly Risedronate GR vs weekly alendronate: 99.7%; estimated savings due to fractures avoided with weekly risedronate GR vs weekly alendronate: 1,202 million euros (1,202,682,218 €).

^‡With weekly risedronate GR, fractures are avoided or QALYs are gained, with lower costs per patient, than with weekly alendronate.

GR: Gastro-resistant; QALYs: Quality-adjusted life-years.